AZAM SADAT MOOSAVI
From the department of Gynecology /oncology, Vali Asr Hospital, Vali Asr reproductive Research center, Tehran University of Medical Sciences, Tehran, Iran.
[ 1 ] - LONG TERM ORAL ETOPOSIDE AS SECOND-LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY
Background: The activity and toxicity of etoposide in women with recurrent ovarian cancer was evaluated in a case series of women with recurrent ovarian cancer who had measurable disease, Methods: All patients had plior platinum-based chemotherapy and developed progressive disease, Etoposide was given as 50mg/day for 21 days every 4 weeks until progression of disease or prohibitive toxicit...
نویسندگان همکار